NCT04635111 - A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

June 1, 2036

Study Completion Date

June 1, 2036

Conditions

HepatotoxicityTenosynovial Giant Cell Tumor

Interventions

DRUG

TURALIO™

This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.

Trial Locations (8)

10467

WITHDRAWN

Montefiore Medical Center, New York

43210

RECRUITING

OSU - James Comprehensive Cancer Center, Columbus

77014

NOT_YET_RECRUITING

Kelsey Seybold Clinic - Pearland, Houston

90403

RECRUITING

Kamalesh K Sankhala MD INC, Santa Monica

NOT_YET_RECRUITING

Sarcoma Oncology Research Center LLC, Santa Monica

90404

RECRUITING

UCLA Hematology and Oncology, Santa Monica

90602

WITHDRAWN

The Oncology Institute of Hope and Innovation, Whittier

02215

RECRUITING

Dana-Farber Cancer Institute, Boston